Overview

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients
Phase:
Phase 3
Details
Lead Sponsor:
Zhejiang Provincial People's Hospital
Treatments:
Abatacept
Janus Kinase Inhibitors